CLINICAL TRIAL: AUTOLOGOUS EBV SPECIFIC CTLS FOR PROPHYLAXIS AND THERAPY OF EBV

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本方案的目的是： 1.从接受或已经接受实体器官移植（SOT）的个体产生自体的、EBV特异性的细胞毒性T细胞系（CTL）。 2.给予患者自体的EBV特异性CTL，以确定这些个体静脉注射的安全性。 3.评价输注CTL的抗病毒和免疫功效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objectives of this protocol are: 1. Generate autologous, EBV-specific, cytotoxic T cell lines (CTLs) from individuals receiving or having received a solid organ transplant (SOT). 2. Administer autologous, EBV-specific CTLs to patients, to determine the safety of intravenous injections in these individuals. 3. Evaluate the antiviral and immunological efficacy of the infused CTLs.